- Home
- HPK vs NUVB Comparison
HPK vs NUVB Comparison
Compare HPK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- NUVB
- Stock Information
- Founded
- HPK 2019
- NUVB 2018
- Country
- HPK United States
- NUVB United States
- Employees
- HPK N/A
- NUVB N/A
- Industry
- HPK Oil & Gas Production
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- HPK Energy
- NUVB Health Care
- Exchange
- HPK Nasdaq
- NUVB Nasdaq
- Market Cap
- HPK 1.1B
- NUVB 1.1B
- IPO Year
- HPK N/A
- NUVB N/A
- Fundamental
- Price
- HPK $7.37
- NUVB $3.27
- Analyst Decision
- HPK Sell
- NUVB Strong Buy
- Analyst Count
- HPK 2
- NUVB 6
- Target Price
- HPK $11.50
- NUVB $8.17
- AVG Volume (30 Days)
- HPK 387.9K
- NUVB 6.7M
- Earning Date
- HPK 11-03-2025
- NUVB 11-05-2025
- Dividend Yield
- HPK 2.14%
- NUVB N/A
- EPS Growth
- HPK N/A
- NUVB N/A
- EPS
- HPK 0.86
- NUVB N/A
- Revenue
- HPK $964,232,000.00
- NUVB $14,355,000.00
- Revenue This Year
- HPK N/A
- NUVB $332.80
- Revenue Next Year
- HPK N/A
- NUVB $360.12
- P/E Ratio
- HPK $8.71
- NUVB N/A
- Revenue Growth
- HPK N/A
- NUVB 900.35
- 52 Week Low
- HPK $7.00
- NUVB $1.54
- 52 Week High
- HPK $16.56
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- HPK 44.48
- NUVB 58.56
- Support Level
- HPK $7.05
- NUVB $3.20
- Resistance Level
- HPK $7.53
- NUVB $3.41
- Average True Range (ATR)
- HPK 0.32
- NUVB 0.26
- MACD
- HPK 0.05
- NUVB -0.03
- Stochastic Oscillator
- HPK 41.07
- NUVB 34.78
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.